Albert Bourla of Pfizer - Big Pharma Reptile

All info related to the new biggest hoax of our time.
SaiGirl
Posts: 363
Joined: Sun Jun 21, 2020 9:42 pm
Location: 21075
Has thanked: 104 times
Been thanked: 128 times
Contact:

Albert Bourla of Pfizer - Big Pharma Reptile

Unread post by SaiGirl »

What did you think of these? Digital glitch? Inserted for OUR entertainment?
User avatar
rachel
Posts: 3872
Joined: Thu Oct 11, 2018 9:04 pm
Location: Liverpool, England
Has thanked: 1364 times
Been thanked: 1647 times

Re: Albert Bourla of Pfizer - Big Pharma Reptile

Unread post by rachel »

It's a distraction. And I think you hit the nail on the head. I'd not considered it, the way he stares, it does suggest he's concentrating on trying to do something, So in that case, it might well be him actually doing what we see; but he's doing it on purpose for effect, not because he's some sort of lizard creature. But also, there might be a digital effect added post-production to emphasise the movement.
User avatar
rachel
Posts: 3872
Joined: Thu Oct 11, 2018 9:04 pm
Location: Liverpool, England
Has thanked: 1364 times
Been thanked: 1647 times

Re: Albert Bourla of Pfizer - Big Pharma Reptile

Unread post by rachel »

While I did suspect it; when up until 2020 did we ever see interviews with CEOs of drug companies? It looks like Albert Bourla was brought in as a new family of The Square specifically for the COVID-19 Soap Opera.

https://www.fiercepharma.com/pharma/pfi ... al-targets
Pfizer's new boss Bourla nets $17.9M in 2019 pay after drugmaker beats all financial targets
Mar 17, 2020

Albert Bourla officially took over as Pfizer CEO first thing in 2019. His total compensation jumped 82% over the previous year, when he was the Big Pharma’s chief operating officer, and reached $17.9 million.

Promotion to Pfizer’s top job wasn’t the only factor that boosted Bourla’s 2019 pay, though. In fact, the drugmaker beat all three financial goals used to evaluate an exec’s cash bonus.


For 2019, Bourla netted $3.63 million in total annual incentive awards on the back of the company’s strong business performance, according to a securities filing (PDF).

Specifically, Pfizer hauled in $52.4 billion in 2019 revenue, ahead of the board’s target of $51.7 billion. Adjusted diluted earnings per share stood at $3.00, versus the $2.81 goal. Cash flow also exceeded the benchmark of $11.6 billion to reach $12.9 billion.

On that account, Bourla’s 2019 bonus was better than what his predecessor, Ian Read, took in the previous year. Because of a slight revenue shortfall—$54.3 billion actual against a $54.5 billion target—Read only received $3 million for his 2018 annual incentive reward, even though his salary was higher.


Before Read transitioned to executive chairman, he was getting a $2 million salary in 2018, his eighth year as CEO of the New York drugmaker. As for Bourla, in his first year holding the reins, his 2019 salary was $1.6 million.

For the 2017-19 performance-based payout, Bourla collected $1.58 million. The actual award value, at $34.72 per share as of the end of February, actually took a hit thanks to the recent coronavirus-related stock market turbulence. Last year, Read’s PSA payout for the 2016-18 period was $14.91 million at $42.93 per share...

Do we think any of this is factual information?

Why would we be allowed to know what Albert Bourla's private earnings are, when we are not allowed to know the ingredients of the concoction his apparent company is injecting into people? On what planet does that make sense?

We clearly don't really know what the guy who turns up in front of a camera claiming to be Albert Bourla, spouting some inane dribble, gets paid. Does he get paid per appearance, or is he on a retainer to push Pfizer products on the media? He's certainly not the brains behind Pfizer, he's just a salesman.


We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla

31 Oct 2023
Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Travis Kelce, acquiring BioHaven and more. Sign up and learn more about the CNBC Investing Club with Jim Cramer.
Post Reply